PUBLICACIONES en Revistas científicas

• Fabián Pitoia, Fernando Jerkovich, Carolina Urciuoli, Florencia Falcón, Anabella Smulever, David Marín Ossa, Andrea Paes de Lima. Impact of histopathologic sample review on the risk of recurrence and response to therapy in patients with differentiated thyroid cancer. World Congress of Thyroid Cancer 2017, 26-28 de julio de 2017, Boston, EEUU.
• Erika Abelleira, Fernanda Bueno, David Marín Ossa, Anabella Smulever, Fabián Pitoia. Dynamic risk assessment in patients with differentiated thyroid cancer without remnant ablation. World Congress of Thyroid Cancer 2017, 26-28 de julio de 2017, Boston, EEUU.
• Angélica Schmidt, Erika Abelleira, Fernanda Bueno, Fabián Pitoia. Progression free survival and overall survival in radioactive iodine-refractory pulmonary metastases of differentiated thyroid carcinoma. World Congress of Thyroid Cancer 2017, 26-28 de julio de 2017, Boston, EEUU.
• J.W.A. Smit M.S. Brose F. Pitoia C-C. Lin I. Sugitani M. Alevizaki Y. Godbert J. Aller R.P. Peeters K. Pazaitou-Panayiotou L. Leenhardt M.M. Fellous Y. De Sanctis M. Schlumberger. Interim baseline characteristics from RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC): A European subgroup analysis. Annals of Oncology, Volume 28, Issue suppl_5, 1 September 2017, mdx368.037, https://doi.org/10.1093/annonc/mdx368.037
• Brose M, Worden F, Bowles D, Wirth L, Owonikoko A, Gianoukakis S, Morita Y, Pitoia F, Smit J, Lin C, Fellous M, De Sanctis Y, Sugitani I, Schlumberger M. Interim baseline characteristics of patients from the United States enrolled in RIFTOS MKI: a global non-interventional study assessing the use of multikinase inhibitors in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer. Thyroid. October. Poster 255
• Pitoia F, Schmidt A. La respuesta al tratamiento en pacientes con cáncer diferenciado de tiroides se mantiene a lo largo del seguimiento independientemente del riesgo de recurrencia inicial. Rev Arg Endocrinol Metab XX Congreso SAEM, Vol 54 (NS), TOR 4: 18. Este trabajo de investigación ganó el segundo premio a mejor investigación clínica.
• Urciuoli C, Jerkovich F, Bueno F, Abelleira E, Pitoia F. Comparación de la evolución de pacientes con microcarcinomas diferenciados de tiroides uni o multifocales luego de ablación vs. no ablación con radioyodo. Rev Arg Endocrinol Metab XX Congreso SAEM, Vol 54 (NS), TOR 5: 19.
• Smulever A, Marin Ossa D, Schmidt A, Pitoia F. Vigilancia active: una nueva alternative en pacientes con carcinoma diferenciado de tiroides. Rev Arg Endocrinol Metab XX Congreso SAEM, Vol 54 (NS), TOR 6: 19.
• Schmidt A, Jerkovich F, Bueno F, Del Río V, Abelleira E, Pitoia F. Efectos adversos raros de los inhibidores multiquinasas en cáncer avanzado de tiroides. Rev Arg Endocrinol Metab XX Congreso SAEM, Vol 54 (NS), TOR 9: 21.
• Zunino A, Ilera V, Faure E, Reyes A, Sala M, Sklate R, Pitoia F, Califano I. Metástasis a distancia en sitios infrecuentes de cáncer diferenciado de tiroides. Rev Arg Endocrinol Metab XX Congreso SAEM, Vol 54 (NS), TOR 71: 50.
• Abelleira E, Jerkovich D, Marin Ossa D, Bueno F, Pitoia F. Riesgo dinámico en pacientes con cáncer diferenciado de tiroides: comparación entre ablacionados vs. no ablacionados de bajo e intermedio riesgo de recurrencia. Rev Arg Endocrinol Metab XX Congreso SAEM, Vol 54 (NS), TOR 73: 50.
• Bueno F, Smulever A, Abelleira E, Jerkovich F, Schmidt A, Pitoia F. Respuesta parcial a Lenvatinib como segunda línea de tratamiento en cáncer diferenciado avanzado de tiroides. Rev Arg Endocrinol Metab XX Congreso SAEM, Vol 54 (NS), P 39: 85.
• Pitoia F, Ilera V, Vazquez A, Faure E, Cavallo A, Califano I y miembros del departamento de Tiroides de SAEM. Comparación de la respuesta inicial luego de la ablación con 30 mCi de 131-I versus no ablación en pacientes con cáncer diferenciado de tiroides de bajo riesgo de recurrencia. Estudio prospectivo multicéntrico. Rev Arg Endocrinol Metab XX Congreso SAEM, Vol 54 (NS), Informe de departamento: 100.
• Abelleira E, Bueno F, Smulever A, Pitoia F. Riesgo dinámico en pacientes con cáncer diferenciado de tiroides no ablacionados /Dynamic risk assessment in patients with differentiated thyroid cancer without remnant ablation. Rev Arg Endocrinol Metab 2017, 54 (2): 69-75.
• Schmidt A, Cross G, Pitoia F. Metástasis a distancia en cáncer diferenciado de tiroides: Diagnóstico y tratamiento. Rev Arg Endocrinol Metab 2017, e-pub ahead of print.
• La Greca A, Pitoia F, Tuttle RM. The “broken chair” in patients with differentiated thyroid cancer. Endocrine. 2017 Jun 14. doi: 10.1007/s12020-017-1345-y.
• Pitoia F, Jerkovich F, Bueno F, Smulever A, Brenta G, Pitoia F. Should age at diagnosis be included in the risk of recurrence classification in patients with differentiated thyroid cancer? Eur Thyroid J. 2017
• Schmidt A, Iglesias L , Klain M , Pitoia F, Schlumberger M. Radioactive-iodine refractory thyroid cancer: an uncommon but challenging situation. Arch Endocrinol Metab. 2017 Jan-Feb;61(1):81-89. doi: 10.1590/2359-3997000000245.
• Pitoia F, Schmidt A, Bueno F, Mocarbel Y, Jerkovich F, Abelleira E. Guía práctica para el manejo de efectos adversos por inhibidores multicinasas (sorafenib y vandetanib) en pacientes con cáncer de tiroides avanzado. Rev Arg Endocrinol Metab 2017, 54:8-20
• Brose MS, Smit JW, Lin CC, Pitoia F, Fellous M, DeSanctis Y, Schlumberger M, Tori M, Sugitani I. Timing of multikinase inhibitor initiation in differentiated thyroid cancer. Endocr Relat Cancer. 2017 Mar 7. pii: ERC-17-0016. doi: 10.1530/ERC-17-0016.
• Fanny Piotrkowski-VialeAdriana ReyesAlicia DiosFabian PitoiaAlicia LowensteinPatricia Glikman. Effects of sample storage and diluents in the reliability of thyroglobulin measurement in the washout of fine needle aspirates. Endocrine 2017 (e-pub ahead of print)

• Pitoia F, Miyauchi A. 2015 American Thyroid Association Guidelines for Thyroid Nodules and Differentiated Thyroid Cancer and Their Implementation in Various Care Settings. Thyroid. 2016 Feb;26(2):319-21. doi: 10.1089/thy.2015.0530. Epub 2015 Dec 17.
• Morosán YJ, Parisi C, Urrutia MA, Rosmarin M, Schnitman M, Serrano L, Luciani W, Faingold C, Pitoia F, Brenta G. Dynamic prediction of the risk of recurrence in patients over 60 years of age with differentiated thyroid carcinoma. Arch Endocrinol Metab. 2016 Feb 23. pii: S2359-9972016005002108. [Epub ahead of print]
• Pitoia F, Jerkovich F. Selective use of sorafenib in the treatment of thyroid cancer. Drug Design, Development and Therapy, published 11 March 2016, Volume 2016:10, Pages 1119—1131.
• Carolina Urciuoli, Erika Abelleira, Maria Celeste Balonga, Graciela Arevalo de Cross, Angelica Schmidt, Monica Sala, Monica Rosales, Patricia Maidana, Viviana Mesch y Fabian Pitoia. Prevalencia de enfermedades tiroideas en una población del área metropolitana de Buenos Aires. Rev Arg Endocrinol Metab 2016, e pub ahead of print: http://dx.doi.org/10.1016/j.raem.2016.05.007.
• Pitoia F, Abelleira E, Cross G. Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH. Endocrine. 2016 Sep 21. [Epub ahead of print]: DOI: 10.1007/s12020-016-1104-5

• Pitoia F, Jerkovich F, Urciuoli C, Schmidt A, Abelleira E, Bueno F, Cross G, Tuttle RM Md. Implementing the Modified 2009 American Thyroid Association Risk Stratification System in thyroid cancer patients with low and intermediate risk of recurrence. Thyroid. 2015 Jul 1. [Epub ahead of print]
• Pitoia F, Bueno F, Schmidt A, Lucas S, Cross G. Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome. Arch Endocrinol Metab. 2015 Aug;59(4):343-6. doi: 10.1590/2359-3997000000057
• Pitoia F, Abelleira E, Jerkovich F, Urciuoli C, Cross G. Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer. Arch Endocrinol Metab. 2015 Aug;59(4):347-50. doi: 10.1590/2359-3997000000059.

• Pitoia F, Abelleira E, Cross G. Recombinant Human Thyroid-Stimulating Hormone-Aided Remnant Ablation Achieves a Response to Treatment Comparable to That with Thyroid Hormone Withdrawal in Patients with Clinically Relevant Lymph Node Metastases. European Thyroid Jounal 2014 Vol 4 Num 4
• Pitoia F, Abelleira E, Bueno F, Urciuoli C, Schmidt A, Niepomniszcze H. Insulin resistance is another factor that increases the risk of recurrence in patients with thyroid cancer. Endocrine 2014 (e-pub ahead of print)
• Pitoia F, Bueno F, Cross G. Long-Term Survival and Low Effective Cumulative Radioiodine Doses to Achieve Remission in Patients With 131-Iodine-Avid Lung Metastasis From Differentiated Thyroid Cancer. Clin Nucl Med. 2014 Jul 3. [Epub ahead of print]
• Pitoia F y col. Consenso intersocietario* sobre tratamiento y seguimiento de pacientes con cáncer diferenciado de tiroides. (Inter Society Consensus for the Management of Patients with Differentiated Thyroid Cancer). Rev Arg Endocrinol Metab 2014, 52: 85-118
• Califano I, Lowenstein A, Deusth S, Abalovich M, Cabezón C, Pitoia F. Impacto de las metástasis óseas en 47 pacientes con cáncer diferenciado de tiroides (Outcome of Bone Metastases in 47 Patients with Differentiated Thyroid Cancer). Rev Arg Endocrinol Metab 2014, 52:51-58
• Pitoia F. Response to sorafenib treatment in advanced metastatic thyroid cancer. Arq Bras Endocrinol Metab 2014 58 (1):38-41.
• Martin Schlumberger, Marcia Brose, Rosella Elisei, Sophie Leboulleux, Markus Luster, Fabian Pitoia, Furio Pacini. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. The Lancet Diabetes and Endocrinology Early Online Publication, 30 January 2014 doi:10.1016/S2213-8587(13)70215-8
• Pitoia Fabián. Carcinoma Diferenciado de Tiroides. Primera Parte (Epidemiología, Enfoque Inicial, Cirugía y Ablación con Radioyodo). Separata Montpellier 2014, Vol 22 (2): 1-36. ISSN 1515-3878.
• Pitoia Fabián. Sorafenib: is a partial response and stabilization of disease greater than 70% a modest response? Endocr Relat Cancer ERC-13-0544 first published on 24 January 2014
• Abelleira E, Cross G, Pitoia F. Disfunción tiroidea en adultos infectados por el virus de inmunodeficiencia humana. Medicina (Buenos Aires) 2014; 74: 315-320.

• Pitoia F, Bueno F, Urciuoli C, Abelleira E, Cross G, Tuttle RM Md. Outcome of patients with differentiated thyroid cancer risk stratified according to the American Thyroid Association and Latin American Thyroid Society risk of recurrence classification systems. Thyroid 2013 (e-pub ahead of print)
• Califano I , Deutsch S , Castro Jozami L , Fassi J , Lowenstein A , Balzaretti M , Novelli JL , Figari M , Olstein G , Sansó G , Barontini M , Iorcansky S , Cabezón C y miembros del Departamento de Tiroides de la Sociedad Argentina de Endocrinología y Metabolismo (SAEM): Abalovich M, Alcaraz G, Brenta G, Calabrese MC, Corino M, Faure E, Frascaroli G, Gauna A, Gutiérrez S, Ilera V, Jaeger M, Kiejzik M, Martínez MP, Orlandi AM, Pitoia F, Puscar A, Roccatagliata G, Ruso Picasso F, Sala M, Sartorio G, Schnitman M, Silva Croome M, Sklate R, Sobrado P, Storani ME, Vázquez A. Carcinoma medular de tiroides: estudio multicéntrico. Presentación y evolución en 219 pacientes. Rev Arg Endocrinol Metab 2013 50:63-70
• Pitoia F, Bueno MF, Abelleira E, Salvai, ME, Bergoglio L, Luster M, Niepomniszcze H. Undetectable pre-ablation thyroglobulin levels in patients with differentiated thyroid cancer: it is not always what it seems. Arq Bras Endocrinol Metab 2013; 57 (4):300-306.
• Pitoia F. Carcinogénesis tiroidea: Más allá de los genes. Rev Arg Endocrinol Metab 2013; 50(NS):33-34.
• Pitoia F, Abelleira E, Tala H, Bueno F, Urciuoli C, Cross G. Biochemical persistence in thyroid cancer: is there anything to worry about? ENDOCRINE 2013, e-pub ahead of print: 10.1007/s12020-013-0097-6.

• Frederik A. Verburg, Markus Dietlein, Lutz Freudenberg, Sophie Leboulleux, Fabian Pitoia, Christoph Reiners, Marcel Stokkel, and Markus Luster. Recombinant Human TSH Versus Thyroid Hormone Withdrawal. J Nucl Med 2012 Published August 30, 2012 as doi:10.2967/jnumed.112.108738
• Pitoia F. Biología Molecular del Carcinoma Diferenciado de Tiroides. Rev Arg Endocrinol Metab 49 (Supl): 23-25.
• Brose MS, Smit J, Capdevila J, Elisei R, Nutting C, Pitoia F, Robinson B, Schlumberger M, Shong YK, Takami H. Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. Expert Review of Anticancer Therapy, September 2012, Vol. 12, No. 9, Pages 1137-1147
• Furio Pacini, Yasuhiro Ito, Markus Luster, Fabian Pitoia, Bruce Robinson, Lori Wirth. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Expert Review of Endocrinology & Metabolism, September 2012, Vol. 7, No. 5, Pages 541-554
• Fabian Pitoia, Robert Marlowe, Erika Abelleira, Eduardo Faure, Fernanda Bueno, Diego Schwarzstein, Ruben Lutfi, Hugo Niepomniszcze. Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer. Journal of Thyroid Research. Volume 2012 (2012), Article ID 481568, 8 pagesdoi:10.1155/2012/481568
• Fabian Pitoia, Andrea Cavallo. Cáncer de tiroides: en búsqueda del tratamiento individualizado. Medicina (Buenos Aires) 2012, 72 (6):503-513.

• Pitoia, Fabián; Cross, Graciela; Salvai, María E.; Abelleira, Erika; Niepomniszcze, Hugo. Patients with familial non-medullary thyroid cancer have an outcome similar to that of patients with sporadic papillary thyroid tumors. Arq Bras Endocrinol Metab vol.55 (3):219-223.
• Rezzónico J, Rezzónico M, Pusiol E, Pitoia F, Niepomniszcze H. Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metab Syndr Relat Disord. 2011 Feb;9(1):69-75. doi: 10.1089/met.2010.0026. Epub 2010 Dec 3.
• Rezzonico J, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Metformin shrinks thyroid nodules in patients with insulin resistance. Clinical Thyroidology. Vol 23 - Issue 6 (June 2011)
• Bahena-García A, Saldívar C, Siller P, Lorcansky S, Pitoia F, Tamez-Pérez HE. Recombinant human TSH in pediatric thyroid cáncer. Rev Med Inst Mex Seguro Soc. 2011 Nov-Dec;49(6):665-7.
• Fabian Pitoia, Erika Abelleira, Hugo Niepomniszcze. Lack of Increase in the Serum Thyroid-Stimulating Hormone Level After Intramuscular Administration of Recombinant Human Thyroid-Stimulating Hormone Doses in a Morbidly Obese Patient. Endocrine Practice 2011 (4): 656-661.

• Fabian Pitoia, MD; Raul Chervin, MD; Selva Nuñez, MD; María E. Salvai, MD; Elias El Tamer, MD; Daniel Schere, MD; Hugo Niepomniszcze, MD, PhD. Development of Graves' Disease Following a Radioiodine Dose for the Shrinkage of a Multinodular Goiter After Using a Novel Protocol. The Endocrinologist 2010; 20(1): 7-9.
• Pitoia F, Ward L. Differences Between Latin American and American Associations’ Thyroid Cancer Guidelines. Thyroid 2010 Apr;20(4):361-2; discussion 362.
• Cross G, Pitoia F, Suarez H et al. High prevalence of thyroid disorders in relatives of patients with familial papillary thyroid cancer. Medicina (Buenos Aires) 2010;70:139-142.
• Rezzónico J, Rezzónico M, Pusiol E, Pitoia F, Niepomniszcze H. Metformin Treatment for Small Benign Thyroid Nodules in Patients with Insulin Resistance. Metab Syndr Relat Disord. 2010 Dec 3
• Dietlein M, Verburg FA, Luster M, Reiners C, Pitoia F, Schicha H. One should not just read what one believes: the nearly irresolvable issue of producing truly objective, evidence-based guidelines for the management of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2011 Jan 18. [Epub ahead of print]
• Niepomniszcze H, Pitoia F. Resolution of Cushing's Syndrome and Exacerbation of Autoimmune Thyroiditis. Thyroid 2011 Feb;21(2):207.

• Rezzónico JN, Rezzónico M, Pusiol E, Pitoia F, Niepomniszcze H. Increased Prevalence of Insulin Resistance in Patients with Differentiated Thyroid Carcinoma. Metab Syndr Relat Disord. 2009 Mar 25. [Epub ahead of print]
• Pitoia F, El Tamer E, Salvai ME, Niempomniszcze H. Protocol for thyroid remnant ablation after recombinant TSH in thyroid carcinoma. Medicina (Buenos Aires) 2009; 69: 148-152
• Rosalinda Camargo, Sandro Corigliano, Celso Friguglietti, Alicia Gauna, Rubén Harach, Fernando Munizaga, Hugo Niepomniszcze, Fabian Pitoia, Eduardo Pretell, Mario Vaisman, Laura Sterian Ward, Nelson Wohllk, Eduardo Tomimori.Latin American Thyroid Society recommendations for the management of thyroid nodules. Arq Bras Endocrinol Metabol. 2009; 53 (9): 1167-1175.
• Fabian Pitoia, Hugo Niepomniszcze. Reporte sobre Mixedema de la Sociedad Clínica de Londres en 1888. Glánd Tir Paratir 2009; (18): 11-15
• Fabián Pitoia and Hugo Niepomniszcze. Recombinant Human TSH: The Argentinean Experience. Thyroid Volume 19, Number 7, 2008, DOI: 10.1089=thy.2008.0259
• Rezzónico J, Rezzónico M, Pusiol E, Pitoia F, Niepomniszcze H. High prevalence of thyroid nodules in patients with achrocordons (skin tags). Possible role of insulin-resistance. Medicina (B Aires). 2009;69(3):302-304.
• Fabián Pitoia, Laura Ward, Nelson Wohllk, Celso Friguglietti, Eduardo Tomimori, Alicia Gauna, Rosalinda Camargo, Mario Vaisman, Rubén Harach, Fernando Munizaga, Sandro Corigliano, Eduardo Pretell, Hugo Niepomniszcze. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arquivos Brasileiros de Endocrinologia y Metabologia. Volume 53 - Número 7 - Octubre de 2009.

• Rezzonico J, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Introducing the Thyroid Gland as Another Victim of the Insulin Resistance Syndrome. Thyroid. 2008 Mar 17 [Epub ahead of print]
• Fabián Pitoia, Elías El Tamer, María Eugenia Salvai, María Belén Zanchetta, Cecilia Goodall, Oscar D. Bruno, Hugo Niepomniszcze. Comparison of two different protocols for the early assessment of disease free status in the follow-up of patients with low risk papillary thyroid carcinoma. Glánd Tir Paratir 2008; (17): 15-21
• Cross G, Suarez H, Pitoia F, Moncet D, Vanegas M, Bruno OD, Niepomniszcze H. Fatal Outcome of a Young Woman with Papillary Thyroid Carcinoma and Graves’ Disease: Possible Implication of “Cross-Signalling” Mechanism. Arq Bras Endocrinol Metab 2008; 52/7:1195-1201
• Pitoia F, Niepomniszcze H. Thyroid cancer: Does the size matter? Thyroid 2008 Dec;18(12):1337. Pearce E et al. Response to Pitoia and Niepomniszcze. Thyroid 2008 Dec,18(12):1338
• Pitoia F, Ilera V, Zanchetta MB, Foffano A, Niepomniszcze H. Optimum recombinant human thyrotropin dose in patients with differentiated thyroid carcinoma and end-stage renal disease. Endocr Pract. 2008 Nov;14(8):961-6.

• Moncet D, Morando DJ, Pitoia F, Katz SB, Rossi MA, Bruno OD. Ketoconazole therapy: an efficacious alternative to achieve eucortisolism in patients with Cushing's syndrome. Medicina (B Aires). 2007;67(1):26-31.
• Chervin RA, Danilowicz K, Pitoia F, Gómez RM, Bruno OD. A study of 34 cases of adrenal incidentalomas Medicina (B Aires). 2007;67(4):341-50.
• Pitoia Fabián. Elevación de la TSH endógena para la evaluación de pacientes con cáncer de tiroides usando inyecciónes de TRH: Se necesita mayor evidencia para recomendar su uso. Revista Argentina de Endocrinología y Metabolismo 44 (3): 201-204
• Pitoia F, Licht S. Evaluación del efecto de la suspensión de la hormona tiroidea en la calidad de vida de pacientes con carcinoma diferenciado de tiroides. Glánd Tir Paratir 2007; (16): 25-29.
• Pitoia Fabián. Microcarcinoma de tiroides: Aspectos Conflictivos. Revista Argentina de Endocrinología y Metabolismo 44 (NS): 19-21.
• Reynaldo M. Gomez, Nora M.E. Albiger, Adriana G. Diaz, Daniel Moncet, Fabian A. Pitoia, Oscar D. Bruno. Effect of Hypercortisolism Control on High Blood. Pressure in Cushing’s Syndrome. Medicina (Buenos Aires) 2007; 67: 439-444

• Pitoia F, Tamer EE, Schere DB, Passerieu M, Bruno OD, Niepomniszcze H. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma. Medicina (B Aires). 2006;66(2):125-30
• Hugo Niepomniszcze, Horacio Suárez, Fabián Pitoia, Analía Pignatta, Karina Danilowicz, Marcos Manavela, Boris Elsner, Oscar D. Bruno. Case Reports: Follicular Carcinoma Presenting as Autonomous Functioning Thyroid Nodule and Containing an Activating Mutation of the TSH Receptor (T620I) and a Mutation of The Ki-RAS (G12C) Genes. Thyroid May 2006, Vol. 16, No. 5: 497-503.
• Fabián Pitoia, Elías El Tamer, Eugenia Salvai, Hugo Niepomniszcze. Un nuevo protocolo para ablación de remanentes tiroideos postquirúrgicos luego de la administración de TSH Recombinante (rhTSH) en pacientes con carcinoma diferenciado de tiroides: Resultados iniciales de un estudio prospectivo Gland Tir Paratir 2006; (15):10-13

• Pitoia F, Moncet D, Glorio R, Graciela Diaz A, Rodriguez Costa G, Carbia S, Cabrera H, Niepomniszcze H. Prevalence of thyroid autoimmunity in patients with pemphigus vulgaris. Medicina (B Aires). 2005;65(4):307-10.
• Pitoia F, Niepomniszcze H. Evaluación de pacientes con carcinoma diferenciado de tiroides con rastreos corporales totales negativos y niveles elevados de tiroglobulina. Glándula Tiroides y Paratiroides 2005; (14): 16-19

• Niepomniszcze H, Sala M, Danilowicz K, Pitoia F, Bruno OD. Epidemiology of palpable goiter in greater Buenos Aires in an iodine-sufficient area. MEDICINA (Buenos Aires) 2004;64:7-12
• Pitoia F, Degrossi O, Niepomniszcze H. Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH? European Journal of Nuclear Medicine and Molecular Imaging 2004; ISSN: 1619-7070 (Paper) 1619-7089 (Online) DOI: 10.1007/s00259-004-1502-4.
• Pitoia F, Danilowicz K, Cross G, Niepomniszcze H. Tiroideopatías autoinmunes vinculadas al uso terapéutica de Interferón alfa 2b en la infección crónica por el virus de la hepatitis C. Gland Tir y Paratir 2004; (12):39-42.
• Pitoia, F. Evaluación bioquímica en el hipo e hipertiroidismo. Bioquímica y Patología Clínica 2004 Vol 68 (1):19-20.
• Pitoia, F. Tiroglobulina, TSH recombinante y cáncer de tiroides. Glándula Tiroides y Paratiroides 2004; (13):33-37

• Iorcansky S, Herzovich V, Pitoia F. Manejo del carcinoma diferenciado de tiroides en niños y adolescentes. Glándulas Tiroides y Paratiroides. 2003 (10):14-18.
• Pitoia F, Niepomniszcze H, Bruno OD. Perspectivas de la terapia génica en tumores tiroideos. Revista Argentina de Endocrinología y Metabolismo. 2003; Vol 40 (4): 219-228.
• Fabián Pitoia. Comentario de Artículo: Consenso sobre el rol de la Tiroglobulina sérica (Tg) como un método de monitoreo para pacientes con carcinoma papilar de tiroides de bajo riesgo. Glánd Tir Paratir 2003 (11): 32-33.

• Quentien MH, Pitoia F, Gunz G, Guillet MP, Enjalbert A, Pellegrini I. Regulation of Prolactin, GH, and Pit-1 Gene Expression in Anterior Pituitary by Pitx2: An Approach Using Pitx2 Mutants. Endocrinology 2002 Aug;143(8):2839-51
• Pitoia F. Uso de TSH recombinante humana en el seguimiento del carcinoma diferenciado de tiroides. Glándulas Tiroides y Paratiroides. 2002, III (8):4-5
• Fabian Pitoia, Hugo Niepomniszcze. Tumor growth after recombinant human TSH. Clinical Endocrinology (Oxford) 2002 Aug;57(2):301
• H Niepomniszcze, F Pitoia, SB Katz, R Chervin and OD Bruno. Primary thyroid disorders in endogenous Cushing's syndrome. European Journal of Endocrinology 2002 Sep; 143(3):305-311
• Fabián Pitoia, Hugo Niepomniszcze. Biología molecular del Carcinoma Diferenciado de Tiroides. Glándulas Tiroides y Paratiroides 2002 (9): 5-8

• Niepomniszcze H, Pitoia F, Goodall C, Manavela M, Bruno OD. Development of Graves' disease after radioiodine treatment for a toxic nodule. Is the hyperthyroidism always triggered by 131-I therapy? 2001. Thyroid (10): 991